View Item 

Show simple item record

Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
dc.contributor.authorOgdie, Alexis
dc.contributor.authorMaksabedian Hernandez, Ervant J.
dc.contributor.authorShaw, Yomei
dc.contributor.authorStolshek, Bradley
dc.contributor.authorMichaud, Kaleb
dc.date.accessioned2022-12-05T16:38:29Z
dc.date.available2023-12-05 11:38:28en
dc.date.available2022-12-05T16:38:29Z
dc.date.issued2022-11
dc.identifier.citationOgdie, Alexis; Maksabedian Hernandez, Ervant J.; Shaw, Yomei; Stolshek, Bradley; Michaud, Kaleb (2022). "Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis." ACR Open Rheumatology 4(11): 935-941.
dc.identifier.issn2578-5745
dc.identifier.issn2578-5745
dc.identifier.urihttps://hdl.handle.net/2027.42/175171
dc.publisherWiley Periodicals, Inc.
dc.titleSide Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175171/1/acr211467.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175171/2/acr211467_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175171/3/acr211467-sup-0001-Disclosureform.pdf
dc.identifier.doi10.1002/acr2.11467
dc.identifier.sourceACR Open Rheumatology
dc.identifier.citedreferenceMichaud K. The National Data Bank for Rheumatic Diseases (NDB). Clin Exp Rheumatol 2016; 34: S100 – 1.
dc.identifier.citedreferenceGeorge MD, Baker JF, Ogdie A. Comparative persistence of methotrexate and tumor necrosis factor inhibitors in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2020; 47: 826 – 34.
dc.identifier.citedreferenceNikiphorou E, Negoescu A, Fitzpatrick JD, Goudie CT, Badcock A, Ostor AJ, et al. Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort. Clin Rheumatol 2014; 33: 609 – 14.
dc.identifier.citedreferenceLie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 671 – 6.
dc.identifier.citedreferenceConway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015; 45: 156 – 62.
dc.identifier.citedreferenceJay R. Methotrexate revisited: considerations for subcutaneous administration in RA. Clin Rheumatol 2015; 34: 201 – 5.
dc.identifier.citedreferenceVisser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009; 27: 1017 – 25.
dc.identifier.citedreferenceAlsadah A, van Merode T, Alshammari R, Kleijnen J. A systematic literature review looking for the definition of treatment burden. Heliyon 2020; 6: e03641.
dc.identifier.citedreferenceOrbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017; 76: 673 – 80.
dc.identifier.citedreferenceOrbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J Rheumatol 2017; 44: 1522 – 8.
dc.identifier.citedreferenceCalasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, et al. Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 2013; 15: R217.
dc.identifier.citedreferenceStriesow F, Brandt A. Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 2012; 4: 3 – 9.
dc.identifier.citedreferenceEngland BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken) 2015; 67: 865 – 72.
dc.identifier.citedreferenceBursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008; 3: 17.
dc.identifier.citedreferenceCurtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis 2010; 69: 43 – 7.
dc.identifier.citedreferenceTilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig 2006; 26: 55 – 62.
dc.identifier.citedreferenceMease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol 2019; 71: 1112 – 24.
dc.identifier.citedreferenceHazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev 2016: CD010227.
dc.identifier.citedreferenceEmery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375 – 82.
dc.identifier.citedreferenceSingh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College Of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019; 71: 5 – 32.
dc.identifier.citedreferenceRajitha P, Biswas R, Sabitha M, Jayakumar R. Methotrexate in the treatment of psoriasis and rheumatoid arthritis: mechanistic insights, current issues and novel delivery approaches. Curr Pharm Des 2017; 23: 3550 – 66.
dc.identifier.citedreferenceCronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020; 16: 145 – 54.
dc.identifier.citedreferenceMerola JF, Ogdie A. SEAM-PsA: seems like methotrexate works in psoriatic arthritis? Arthritis Rheumatol 2019; 71: 1027 – 9.
dc.identifier.citedreferenceMaksabedian Hernandez EJ, Tkacz J, Lopez-Gonzalez L, Higgins K, Ogdie A, Stolshek BS. Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naive patients. Am J Manag Care 2020; 26: e252 – 7.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr211467.pdf
Size:
664.1KB
Format:
PDF
View/Open
Name:
acr211467_am.pdf
Size:
949.8KB
Format:
PDF
View/Open
Name:
acr211467-sup-0001-Disclosuref ...
Size:
935.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.